Deferiprone

Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat iron overload in thalassaemia major.[1] It was first approved for use in treating thalassaemia major in 1994[2] and had been licensed for use in Europe and Asia for many years while awaiting approval in Canada and the United States.[1] On October 14, 2011, it was approved for use in the US under the FDA's accelerated approval program.[3]

Deferiprone
Clinical data
Trade namesFerriprox
AHFS/Drugs.comInternational Drug Names
License data
Pregnancy
category
  • US: D (Evidence of risk)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    MetabolismGlucuronidation
    Elimination half-life2 to 3 hours
    ExcretionRenal (75 to 90% in 24 hours)
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    ECHA InfoCard100.157.470
    Chemical and physical data
    FormulaC7H9NO2
    Molar mass139.152 g/mol g·mol−1
    3D model (JSmol)
     NY (what is this?)  (verify)

    Controversy

    Deferiprone was at the center of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and the pharmaceutical company Apotex, that started in 1996 and delayed approval of the drug in North America.[4] Olivieri's data suggested deferiprone leads to progressive hepatic fibrosis.[5][6][7]

    See also

    References
    1. Savulescu, J (2004). "Thalassaemia major: The murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
    2. Staff, Cipla. Cipla's History Archived 2015-10-27 at the Wayback Machine
    3. FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
    4. Viens, A M; Savulescu, J (2004). "Introduction to the Olivieri symposium". Journal of Medical Ethics. 30 (1): 1–7. doi:10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
    5. Brittenham, G. M; Nathan, D. G; Olivieri, N. F; Porter, J. B; Pippard, M; Vichinsky, E. P; Weatherall, D. J (2003). "Deferiprone and hepatic fibrosis". Blood. 101 (12): 5089–90, author reply 5090–1. doi:10.1182/blood-2002-10-3173. PMID 12788794.
    6. Wanless, I. R; Sweeney, G; Dhillon, A. P; Guido, M; Piga, A; Galanello, R; Gamberini, M. R; Schwartz, E; Cohen, A. R (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood. 100 (5): 1566–9. doi:10.1182/blood-2002-01-0306. PMID 12176871.
    7. Cribb, Robert (2019-02-27). "UHN patients given unlicensed drug that led to diabetes, liver dysfunction and one death, study finds". The Star. Toronto. Retrieved 2019-02-27.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.